Using berberine nanomedicine to reduce food allergies
Official title: IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies
Funded at General Nutraceutical Technology, LLC · NIH-10840330 · Data updated 2026-11-12
This study is testing a new pill made with a special ingredient called berberine to help people with food allergies, especially those allergic to peanuts and tree nuts, by making their immune system less reactive to these foods.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | General Nutraceutical Technology, LLC NIH-funded |
| Lab location | 1 site (Briarcliff Manor, UNITED STATES) |
| Project start | May 11, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $894,193 |
| NIH project number | 5R44AI177183-02 |
| Project ID | NIH-10840330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older who suffer from severe food allergies, particularly to peanuts and tree nuts.
✕Less likely to help
Patients with food allergies who are not responsive to immunotherapy or those with allergies to foods other than peanuts and tree nuts may not benefit from this research.
What this research studies
This research investigates a new oral treatment for food allergies using a compound called berberine, which is delivered through nanoparticles to enhance its effectiveness. The approach aims to suppress the immune response that causes severe allergic reactions, particularly by targeting specific immune cells responsible for producing harmful antibodies. By improving the bioavailability of berberine, the treatment hopes to provide a safer and more effective option for individuals suffering from food allergies, especially those with peanut and tree nut allergies.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly reduces the risk of severe allergic reactions in patients with food allergies.
How similar studies have gone: While the approach of using nanomedicine for allergy treatment is innovative, preliminary studies have shown promising results in animal models, indicating potential for success in human applications.
Where this research is happening
-
General Nutraceutical Technology, LLC
Briarcliff Manor, United States Active
Researchers
- Principal investigator: Yang, Nan — General Nutraceutical Technology, LLC
- Study coordinator: Yang, Nan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.